TİMOLOL/BRİNZOLOMİD KOMBİNASYONU İLE TİMOLOL/DORZOLOMİD KOMBİNASYONUN GÖZ TANSİYONU AÇISINDAN KARŞILAŞTIRILMASI

Öz

Amaç: Bu çalışmanın amacı timolol/dorzolamid ve
timolol/brinzolamid sabit kombinasyon ilaçlarının
göz içi basıncı üzerine etkisini karşılaştırmaktır.
Gereç ve Yöntem: Bu retrospektif bir çalışmadır.
Monoterapiye rağmen intraoküler basıncı yüksek
olan ve kombinasyon tedavisine geçilen primer açık
açılı glokom hastaları çalışmaya dahil edildi. .
Toplam 50 hastanın 50 gözü çalışmaya alınmıştır
(timolol /dorzolamid grubunda 26, timolol
/brinzolamid grubunda 24 hasta). İridokorneal açıda
sineşi olmayan, hikayesinde başka herhangi bir göz
hastalığı olan veya herhangi bir göz ameliyatı
geçiren hastalar çalışmaya dahil edilmemiştir.
Kaydedilmiş olan 4.hafta ve 4.ay göz içi basınç
değerleri karşılaştırıldı.

Bulgular: Bazal intraoküler basınç değeri
timolol/dorzolamid grubunda 23,2±3,3 (17-28
mmHg), timolol/brinzolamid grubunda ise 23,1±2,8
(17-28 mmHg) olarak bulundu. 4.hafta sonunda
elde edilen intraoküler basınç değerleri timolol/
dorzolomid grubunda 15,3 ±2,3 (11-20mmHg),
timolol/brinzolomid grubunda ise 15,8±2,7(11-
19mmHg) idi. Bu değerler arasında istatistiksel
olarak anlamlı fark bulunamadı. 4.ay sonunda elde
edilen İOB değerleri timolol/dorzolamid grubunda
15,8±3,1 (11-21mmHg), timolol/brinzolomid
grubunda ise 16,1±2,8 (12-22mmHg) olarak
bulundu. Bu değerler arasında istatistiksel olarak
anlamlı fark bulunamadı.
Sonuç: Her iki ilaçta intraoküler basıncı başarılı bir
şekilde düşürmüştür fakat 4.hafta ve 4.ay değerleri
arasında istatistiksel olarak anlamlı bir fark yoktur.

Anahtar Kelimeler

• Timolol/Brinzolomid
• Timolol/Dorzolomid
• Göz Tansiyonu

Comparison the effect of timolol/brinzolomid and timolol/ dorzolamid fixedcombination drugs on intraocular pressure

Abstract

Objective: The aim of this study is to compare the effect timolol/brinzolomid fixed-combination drugs on intraocular pressure. Materials and Methods: This is a retrospective study. The primary open angle glaucoma patients that were switched to fixed-combination drugs due to high intraocular pressure despite monotherapy were included to the study. The intraocular pressure records of 4.week and 4.month were compared. Results: The baseline intraocular pressure levels were timolol/dorzolamid group and 23,1±2,8 (17-28 mmHg) in timolol/brinzolamid group. After 4.weeks of combination treatment intraocular pressure levels were 15,3 ±2,3 mmHg (1120mmHg) in timolol/ dorzolomid and 15,8±2,7(1119mmHg) in timolol/brinzolomid. After 4.nmonths of combination treatment intraocular pressure levels were 15,8±3,1 (11-21mmHg) in timolol/dorzolamid group timolol/brinzolomid group. There statistically significant difference between the groups. Conclusion: Both fixed combination drugs decreased the intraocular pressure successfully but there was no statistically significant difference between intraocular pressure levels at 4.week and 4.month. Key dorzolamid

Keywords

• timolol/brinzolomid
• timolol/ dorzolamid
• intraocular pressure

References

1. Sanseau A, Sampaolesi J, Suzuki ER Jr, Lopes JF, Borel H. Preference for a fixed combination of
2. brinzolamide/timolol versus dorzolamide/timolol among patients with open-angle glaucoma or ocular
3. hypertension. Clin Ophthalmol. 2013;7:357-62.
4. Kass MA, Heuer DK, Higginbotham EJ. The Ocular Hypertension Treatment Study: a randomized
5. trial determines that topical ocular hypotensive medication delays or prevents the onset of primary
6. open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713.
7. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 3rd ed. 87-88.
8. Boyle JE, Ghosh K, Gieser DK, Adamsons IA. Ophthalmology A randomized trial comparing the

9. dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide.
10. Ophthalmology. 1999;106:10-6.
11. Strohmaier K, Snyder E, DuBiner H, Adamsons I. The efficacy and safety of the dorzolamidetimolol
12. combination versus the concomitant administration of its components. Dorzolamide-Timolol
13. Study Group.Ophthalmology. 1998;105(10):1936-44.
14. Kaback M, Scoper SV, Arzeno G, et al. Brinzolamide 1%/Timolol 0.5% Study Group. Intraocular
15. pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with
16. brinzolamide 1% and timolol 0.5%. Ophthalmology. 2008;115:1728–1734, 1734.
17. Vold SD, Evans RM, Stewart RH, Walters T, Mallick S. A one-week comfort study of BID-dosed
18. brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed
19. dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular
20. hypertension. J Ocul Pharmacol Ther. 2008 ;24:601-5.
21. Manni G, Denis P, Chew P, Sharpe ED, Orengo-Nania S, Coote MA, Laganovska G, Volksone L,
22. Zeyen T, Filatori I, James J, Aung T. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed
23. combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular
24. hypertension. J Glaucoma. 2009 ;18:293-300.
25. Barnebey H1, Kwok SY. Patients' acceptance of a switch from dorzolamide to brinzolamide for the
26. treatment of glaucoma in a clinical practice setting. Clin Ther. 2000 ;22:1204-12.
27. Mulaney J, Sonty S, Ahmad A, Stewart JA, Stewart WC. Comparison of daytime efficacy and
28. safety of dorzolamide/timolol maleate fixed combination versus latanoprost. Eur J Ophthalmol.
29. ;18:556–62.
30. Parmaksiz S, Yuksel N, Karabas VL, Ozkan B, Demirci G, Caglar Y. A comparison of travoprost,
31. latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfolitation
32. glaucoma. Eur J Ophthalmol. 2006;16:73–80